Hairy Cell Leukemia (HCL): Market Insights, Epidemiology and Forecast to 2028 - Key Players are Working Robustly on New Therapies with Novel Mechanism of Action - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 15, 2019--The “Hairy Cell Leukemia (HCL) - Market Insights, Epidemiology and Market Forecast-2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hairy Cell Leukemia (HCL) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hairy Cell Leukemia (HCL) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography CoveredThe United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan
Study Period: 2017-2028
According to this research, the incident population of Hairy Cell Leukemia (HCL) was estimated to be 2,378 [7MM] in 2018. United States accounts for the highest HCL cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Hairy Cell Leukemia, followed France.
In the first-line setting for patients, Purine analogs are the mainstay of HCL therapy for physically fit and symptomatic HCL patients, conferring in most cases a longer overall survival (OS). The treatment is based on either cladribine (2-CdA) or Pentostatin (DCF).
Among the 7 major markets, the United States is estimated to have the maximum market share of Hairy Cell Leukemia, followed by EU5 and Japan. There are only various therapies approved for the treatment of patients with Hairy Cell Leukemia in the United States that include Leustatin (Janssen); Nipent (Pfizer); Intron-A (Merck); Roferon-A (Roche) and Lumoxiti (AstraZeneca).
Leustatin and Nipent are the purine anlaogs been approved as the first line of therapy for the treatment of Hairy Cell Leukemia. Lumoxiti (moxetumomab pasudotox-tdfk) developed by AstraZeneca is the first in class therapy approved for the treatment of Hairy Cell Leukemia. Detailed chapters for all of these drugs, along with the upcoming therapy i.e., Ibrutinib (Imbruvica) as well as another promising candidate Vemurafenib (Zelboraf, Roche) have been covered in the report.
The Hairy Cell Leukemia (HCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the global market of Hairy Cell Leukemia (HCL) was estimated to be USD 48.12 million in 2018. The United States accounts for the largest market size of Hairy Cell Leukemia, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Currently, the effective management of Hairy Cell Leukemia mainly involves the usage of Purine Analogues (Cladribine and Pentostatin), Rituximab, and Interferon-alpha 2b. These therapies are used as either monotherapy or in combination as various lines of treatment.
The dynamics of Hairy Cell Leukemia market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Key players are working robustly on new therapies with novel mechanism of action, including Vemurafenib (Zelboraf; Roche), Ibrutinib (Imbruvica; Pharmacyclics) and Moxetumomab (Lumoxiti; AstraZeneca, the drug is launched in the US recently, but not in other markets).
Lumoxiti (Moxetumomab) became the first ever drug therapy to receive USFDA approval as a third line of treatment in September 2018. The drug is a first-in-class medicine for hairy cell leukaemia and marks first new treatment option for patients in over 20 years.
The market size of Hairy Cell Leukemia (HCL) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
Vemurafenib is being developed as the first line of therapy, while Ibrutinib is expected to enter the market as second line of therapy; Both the therapies are already launched in the market for the treatment of other respective indications.
Overall, with the launch of new therapies in various line of treatment (LoT), it is estimated that these therapies shall gradually replace the market of traditional therapies that are presently being used as 1st LoT, 2nd LoT and 3rd LoT, in the coming years.
Report InsightsPatient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies
Report Key Strengths10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition
Report AssessmentCurrent Treatment Practices Unmet Needs Detailed Pipeline Product Profiles Market Attractiveness Market Drivers and Barriers
Companies MentionedAstraZeneca Janssen Pfizer Merck Roche Johnson and Johnson
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l543m3/hairy_cell?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190215005144/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Leukemia Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/15/2019 04:46 AM/DISC: 02/15/2019 04:46 AM